Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial.
Thiery-Vuillemin A, de Bono J, Hussain M, Roubaud G, Procopio G, Shore N, Fizazi K, Dos Anjos G, Gravis G, Joung JY, Matsubara N, Castellano D, Degboe A, Gresty C, Kang J, Allen A, Poehlein C, Saad F. Thiery-Vuillemin A, et al. Among authors: dos anjos g. Lancet Oncol. 2022 Mar;23(3):393-405. doi: 10.1016/S1470-2045(22)00017-1. Epub 2022 Feb 11. Lancet Oncol. 2022. PMID: 35157830 Clinical Trial.
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.
Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, Özgüroğlu M, Kang J, Burgents J, Gresty C, Corcoran C, Adelman CA, de Bono J; PROfound Trial Investigators. Hussain M, et al. N Engl J Med. 2020 Dec 10;383(24):2345-2357. doi: 10.1056/NEJMoa2022485. Epub 2020 Sep 20. N Engl J Med. 2020. PMID: 32955174 Free article. Clinical Trial.
Will the medical student in the team please stand up?
dos Anjos G, Peeters M, Wyatt JC, Sharma RA. dos Anjos G, et al. Lancet Oncol. 2012 Aug;13(8):757-8. doi: 10.1016/S1470-2045(12)70355-8. Lancet Oncol. 2012. PMID: 22846828 No abstract available.
Reply by Authors.
Guglielmetti GB, Dos Anjos GC, Sawczyn G, Rodrigues G, Cardili L, Cordeiro MD, Neves LCO, Pontes Junior J, Fazoli A, Coelho RF, Srougi M, Nahas WC. Guglielmetti GB, et al. Among authors: dos anjos gc. J Urol. 2022 Aug;208(2):267. doi: 10.1097/JU.0000000000002695.03. Epub 2022 May 24. J Urol. 2022. PMID: 35607900 No abstract available.
REPLY BY THE AUTHORS: RE: Impact of COVID-19 on a urology residency program.
Danilovic A, Torricelli FCM, Dos Anjos G, Cordeiro MD, Machado MG, Srougi M, Nahas WC. Danilovic A, et al. Among authors: dos anjos g. Int Braz J Urol. 2021 Jul-Aug;47(4):911-912. doi: 10.1590/S1677-5538.IBJU.2021.0060.1. Int Braz J Urol. 2021. PMID: 33848091 Free PMC article. No abstract available.
Impact of COVID-19 on a urology residency program.
Danilovic A, Torricelli FCM, Dos Anjos G, Cordeiro MD, Machado MG, Srougi M, Nahas WC. Danilovic A, et al. Among authors: dos anjos g. Int Braz J Urol. 2021 Mar-Apr;47(2):448-453. doi: 10.1590/S1677-5538.IBJU.2020.0707. Int Braz J Urol. 2021. PMID: 33284549 Free PMC article. No abstract available.
23 results